• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Development of personalized medicine for cancer chemotherapy according to a variety of sensitivity and pharmacokinetics

Research Project

Project/Area Number 21590167
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Medical pharmacy
Research InstitutionKumamoto University

Principal Investigator

HAMADA Akinobu  熊本大学, 医学部附属病院, 准教授 (00322313)

Co-Investigator(Kenkyū-buntansha) SAITO Hideyuki  熊本大学, 医学部附属病院, 教授 (40225727)
佐々木 治一郎  熊本大学, 大学院・生命科学研究部, 助教 (60419637)
川口 辰哉  熊本大学, 医学部附属病院, 准教授 (50244116)
Co-Investigator(Renkei-kenkyūsha) SASAKI Ji-i  北里大学, 医学部, 准教授 (60419637)
KAWAGUCHI Tatsuya  熊本大学, 医学部附属病院, 准教授 (50244116)
Research Collaborator ANDO Yuichi  名古屋大学, 医学部附属病院, 准教授 (10360083)
Project Period (FY) 2009 – 2011
Project Status Completed (Fiscal Year 2011)
Budget Amount *help
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2011: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2010: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2009: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
Keywordsオーダーメード医療 / 分子標的薬 / 癌 / 薬剤反応性
Research Abstract

Objectives : We analyzed the association of ABCB1 polymorphisms with erlotinib-induced toxicity and the pharmacokinetics in patients with non-small cell lung cancer.
Methods : After erlotinib 150 mg was administered to 50 patients, ABCB1 polymorphisms were analyzed via either TaqMan assays or direct nucleotide sequencing. Plasma concentrations were measured by high-performance liquid chromatography.
Results : The trough concentration at steady state(Css) in patients with the ABCB1 1236TT-2677TT-3435TT genotype was higher as compared to others groups(P=0. 021) and this patients carrying this genotype had a higher risk of development for higher grade 2 toxicity(p=0. 012).
Conclusion : The present study suggested that the ABCB1 1236TT-2677TT-3435TT genotype was associated with higher concentration and the risk of development for higher toxicity in patients treated with erlotinib.

Report

(4 results)
  • 2011 Annual Research Report   Final Research Report ( PDF )
  • 2010 Annual Research Report
  • 2009 Annual Research Report
  • Research Products

    (57 results)

All 2012 2011 2010 2009

All Journal Article (28 results) (of which Peer Reviewed: 27 results) Presentation (27 results) Patent(Industrial Property Rights) (2 results)

  • [Journal Article] Effects of genetic variants in SLC22A2 organic cation transporter2and SLC47A1 multidrug and toxin extrusion1transporter on cisplatin-induced adverse events2012

    • Author(s)
      Iwata K, Aizawa K, Kamitsu S, Ji ngami S, Fukunaga E, Yoshida M, Yoshimura M, Hamada A, Saito H
    • Journal Title

      Clin Exp Nephrol

      Volume: (accepted)

    • Related Report
      2011 Final Research Report
    • Peer Reviewed
  • [Journal Article] Erlotinib-induced acute interstitial lung disease associated with extreme elevation of the plasma concentration in an elderly non-small-cell lung cancer patient2012

    • Author(s)
      Tsubata Y, Hamada A, Sutani A, Isobe T
    • Journal Title

      Journal of Cancer Research and Therapeutics

      Volume: 8 Pages: 154-156

    • Related Report
      2011 Final Research Report
    • Peer Reviewed
  • [Journal Article] Association of ABCB1 polymorphisms with erlotinib pharmacokinetics and toxicity in Japanese patients with non-small cell lung cancer2012

    • Author(s)
      Hamada A, Sasaki J, Saeki S, Iwamoto N, Inaba M, Ushijima S, Urata M, Kishi H, Fujii S, Semba H, Kashiwabara K, Tsubata Y, Kai Y, Isobe T, Kourogi H, Saito H
    • Journal Title

      Pharmacogenomics

      Volume: 13 Pages: 615-624

    • Related Report
      2011 Final Research Report
    • Peer Reviewed
  • [Journal Article] Erlotinib-induced acute interstitial lung disease associated with extreme elevation of the plasma concentration in an elderly non-small-cell lung cancer patient2012

    • Author(s)
      Tsubata Y
    • Journal Title

      Journal of Cancer Research and Therapeutics

      Volume: (印刷中)

    • Related Report
      2011 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Association of ABCB1 polymorphisms with erlotinib pharmacokinetics and toxicity in Japanese patients with non-small cell lung cancer2012

    • Author(s)
      Hamada A
    • Journal Title

      Pharmacogenomics

      Volume: (印刷中)

    • Related Report
      2011 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Genetic polymorphisms in metabolic and cellular transport pathway of methotrexate impact clinical outcome of methotrexate monotherapy in Japanese patients with rheumatoid arthritis2012

    • Author(s)
      Kato T
    • Journal Title

      Drug Metab Pharmacokinet

      Volume: (印刷中)

    • Related Report
      2011 Annual Research Report
    • Peer Reviewed
  • [Journal Article] The relationship between treatment time of gemicitabine and development of hematologic toxicity in cancer patients2012

    • Author(s)
      Iwata K
    • Journal Title

      Biol Pharm Bull

      Volume: (印刷中)

    • Related Report
      2011 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Alleviation of cisplatin-induced acute kidney injury using phytochemical polyphenols is accompanied by reduced accumulation of indoxyl sulfate in rats2012

    • Author(s)
      Kusumoto M
    • Journal Title

      Clin Exp Nephrol

      Volume: (印刷中)

    • Related Report
      2011 Annual Research Report
    • Peer Reviewed
  • [Journal Article] The relationship between treatment time of gemicitabine and development of hematologic toxicity in cancer patients2011

    • Author(s)
      Iwata K, Aizawa K, Sakai S, Jingami S, Fukunaga E, Yoshida M, Hamada A, Saito H
    • Journal Title

      Biol Pharm Bull

      Volume: 34 Pages: 1765-1768

    • Related Report
      2011 Final Research Report
    • Peer Reviewed
  • [Journal Article] Pharmacokinetic impact of SLCO1A2 polymorphisms on imatinib disposition in patients with chronic myeloid leukemia2011

    • Author(s)
      Yamakawa Y, Hamada A, Shuto T, Yuki M, Uchida T, Kai H, Kawaguchi T, Saito H
    • Journal Title

      Clin Pharmacol Ther

      Volume: 90 Pages: 157-163

    • NAID

      120005952465

    • Related Report
      2011 Annual Research Report 2011 Final Research Report
    • Peer Reviewed
  • [Journal Article] High-performance liquid chromatographic assay for the determination of nilotinib in human plasma2011

    • Author(s)
      Yuki M, Yamakawa Y, Uchida T, Nambu T, Kawaguchi T, Hamada A, Saito H
    • Journal Title

      Biol Pharm Bull

      Volume: 34 Pages: 1126-1128

    • NAID

      130000738108

    • Related Report
      2011 Annual Research Report 2011 Final Research Report
    • Peer Reviewed
  • [Journal Article] Erlotinib efficacy and cerebrospinal fluid concentration in lung adenocarcinoma patients developing leptomeningeal metastases during gefitinib therapy2011

    • Author(s)
      Masuda T, Hattori N, Hamada A, Iwamoto H, Ohshimo S, Kanehara M, Ishikawa N, Fujitaka K, Haruta Y, Murai H, Kohno N
    • Journal Title

      Cancer Chemother Pharmacol

      Volume: 67 Pages: 1465-1469

    • Related Report
      2011 Final Research Report
    • Peer Reviewed
  • [Journal Article] Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia2011

    • Author(s)
      Yamakawa Y, Hamada A, Nakashima R, Yuki M, Hirayama C, Kawaguchi T, Saito H
    • Journal Title

      Ther Drug Monit

      Volume: 33 Pages: 244-250

    • NAID

      120005952466

    • Related Report
      2011 Final Research Report 2010 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Association of SLCO1B3 polymorphism with intracellular accumulation of imatinib in leukocytes in patients with chronic myeloid leukemia2011

    • Author(s)
      Nambu T, Hamada A, Nakashima R, Yuki M, Kawaguchi T, Mitsuya H, Saito H
    • Journal Title

      Biol Pharm Bull

      Volume: 34 Pages: 114-119

    • NAID

      130000402273

    • Related Report
      2011 Final Research Report
    • Peer Reviewed
  • [Journal Article] Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy2011

    • Author(s)
      Masuda, Takeshi
    • Journal Title

      Cancer Chemother Pharmacol

      Volume: (in press)

    • Related Report
      2010 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Association of SLCO1B3 Polymorphism with Intracellular Accumulation of Imatinib in Leukocytes in Patients with Chronic Myeloid Leukemia2011

    • Author(s)
      Nambu, Takeru
    • Journal Title

      Biol Pharm Bull

      Volume: 34 Pages: 114-119

    • Related Report
      2010 Annual Research Report
    • Peer Reviewed
  • [Journal Article] エルロチニブの薬物動態ならびに有害事象およぼすABCトランスポータ遺伝子多型の影響2011

    • Author(s)
      濱田哲暢
    • Journal Title

      腫瘍内科

      Volume: 6 Pages: 35-44

    • Related Report
      2010 Annual Research Report
  • [Journal Article] Prospective evaluation of pharmacokinetically guided dosing of carboplatin in Japanese patients with cancer2010

    • Author(s)
      Shimokata T, Ando Y, Yasuda Y, Hamada A, Kawada K, Saito H, Matsuo S, Kondo M, Imaizumi K, Hasegawa Y
    • Journal Title

      Cancer Sci

      Volume: 101 Pages: 2601-2605

    • NAID

      10027834680

    • Related Report
      2011 Final Research Report
    • Peer Reviewed
  • [Journal Article] Serum concentrations of erlotinib at a dose of25mg daily2010

    • Author(s)
      Costa DB, Kobayashi S, Yeo WL, Hamada A
    • Journal Title

      J Thorac Oncol

      Volume: 5 Pages: 1311-1312

    • Related Report
      2011 Final Research Report
    • Peer Reviewed
  • [Journal Article] Contribution of BCR-ABL-independent Activation of ERK1/2 to Acquired Imatinib Resistance in K562Chronic Myeloid Leukemia Cells2010

    • Author(s)
      Nambu T, Araki N, Nakagawa A, Kuniyasu A, Kawaguchi T, Hamada A, Saito H
    • Journal Title

      Cancer Sci

      Volume: 10 Pages: 137-142

    • NAID

      10027199844

    • Related Report
      2011 Final Research Report
    • Peer Reviewed
  • [Journal Article] Contribution of BCR-ABL-independent activation of ERK1/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cells2010

    • Author(s)
      Nambu, Takeru
    • Journal Title

      Cancer Sci 125

      Pages: 137-142

    • Related Report
      2009 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Co-administration of irinotecan decreases the plasma concentration of an active metabolite of amrubicin, amrubicinol in rats2010

    • Author(s)
      Maeda, Yukiko
    • Journal Title

      Cancer Chemother Pharmacol 65

      Pages: 953-959

    • Related Report
      2009 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Co-administration of irinotecan decreases the plasma concentration of an active metabolite of amrubicin, amrubicinol in rats2009

    • Author(s)
      Maeda Y, Hamada A, Sanematsu E, Sasaki J, Yokoo K, Hira A, Saito H
    • Journal Title

      Can cer Chemother Pharmacol

      Volume: 65 Pages: 653-659

    • NAID

      120002469644

    • Related Report
      2011 Final Research Report
    • Peer Reviewed
  • [Journal Article] P-Glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines2009

    • Author(s)
      Fujimoto H, Higuchi M, Watanabe H, Koh Y, Ghosh AK, Mitsuya H, Tanoue N, Hamada A, Saito H
    • Journal Title

      Biol Pharm Bull

      Volume: 32 Pages: 1588-1593

    • NAID

      130000117288

    • Related Report
      2011 Final Research Report
    • Peer Reviewed
  • [Journal Article] Relationship between an effective dose of imatinib, body surface area, and trough drug levels in patients with chronic myeloid leukemia2009

    • Author(s)
      K awaguchi T, Hamada A, Hirayama C, Nakashima R, Nambu T, Yamakawa Y, Watanabe H, Horikawa H, Mitsuya H, Saito H
    • Journal Title

      Int J Hematol

      Volume: 89 Pages: 642-8

    • NAID

      10025161955

    • Related Report
      2011 Final Research Report
    • Peer Reviewed
  • [Journal Article] P-Glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines2009

    • Author(s)
      Fujimoto, Hiromi
    • Journal Title

      Biol Pharm Bull 32

      Pages: 1588-1593

    • Related Report
      2009 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Relationship between an effective dose of imatinib, body surface area, and trough drug levels in patients with chronic myeloid leukemia2009

    • Author(s)
      Kawaguchi, Tatsuya
    • Journal Title

      Int J Hematol 89

      Pages: 642-648

    • NAID

      10025161955

    • Related Report
      2009 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Effects of oral administration of S-1 on the pharmacokinetics of SN-38, irinotecan active metabolite, in patients with advanced colorectal cancer2009

    • Author(s)
      Yokoo, Koji
    • Journal Title

      Ther Drug Monit 31

      Pages: 400-403

    • Related Report
      2009 Annual Research Report
    • Peer Reviewed
  • [Presentation] 呼吸器疾患の最前線:基礎から臨床まで 抗悪性腫瘍悪の薬効・毒性を薬物動態から考察する2011

    • Author(s)
      濱田哲暢
    • Organizer
      第65回日本呼吸器学会・日本結核病学会九州支部秋期講演会
    • Place of Presentation
      崇城大学ホール(熊本)
    • Year and Date
      2011-11-12
    • Related Report
      2010 Annual Research Report
  • [Presentation] 新規経口分子標的薬抗がん剤の体内動態とPharmacogenomics2011

    • Author(s)
      濱田哲暢
    • Organizer
      日本臨床腫瘍学会
    • Place of Presentation
      パシフィコ横浜(横浜)(招待講演)
    • Year and Date
      2011-07-21
    • Related Report
      2011 Annual Research Report
  • [Presentation] 上皮成長因子受容体阻害薬(EGFR-TKI)におけるTDM/PGx研究の展望2011

    • Author(s)
      濱田哲暢
    • Organizer
      日本TDM学会・学術大会
    • Place of Presentation
      広島国際会議場(広島)(招待講演)
    • Year and Date
      2011-06-01
    • Related Report
      2011 Annual Research Report
  • [Presentation] Metabolic profiles as the predictive biomarkers of erlotinib-induced adverse effects in non-small cell lung cancer (NSCLC) patients2011

    • Author(s)
      Hamada A
    • Organizer
      American Society of Clinical Oncology
    • Place of Presentation
      マコーミックプレス(シカゴ)、米国
    • Year and Date
      2011-06-01
    • Related Report
      2011 Annual Research Report
  • [Presentation] 副作用とトランスポータ親和性を指標とし抗がん剤個別化治療戦略2011

    • Author(s)
      濱田哲暢
    • Organizer
      薬物動態学会ワークショップ
    • Place of Presentation
      東京大学(東京)(招待講演)
    • Year and Date
      2011-05-12
    • Related Report
      2011 Annual Research Report
  • [Presentation] 新規経口分子標的薬抗がん剤の体内動態とPharmacogenomics2011

    • Author(s)
      濱田哲暢
    • Organizer
      第9回日本臨床腫瘍学会
    • Place of Presentation
      横浜(パシフィコ横浜)
    • Related Report
      2011 Final Research Report
  • [Presentation] 上皮成長因子受容体阻害薬(EGFR-TKI)におけるTDM/PGx研究の展望2011

    • Author(s)
      濱田哲暢
    • Organizer
      第28回日本TDM学会・学術大会
    • Place of Presentation
      広島(広島国際会議場)
    • Related Report
      2011 Final Research Report
  • [Presentation] 副作用とトランスポータ親和性を指標とし抗がん剤個別化治療戦略2011

    • Author(s)
      濱田哲暢
    • Organizer
      第25回薬物動態学会ワークショップ
    • Place of Presentation
      東京(東京大学)
    • Related Report
      2011 Final Research Report
  • [Presentation] 呼吸器疾患の最前線:基礎から臨床まで抗悪性腫瘍悪の薬効・毒性を薬物動態から考察する2010

    • Author(s)
      濱田哲暢
    • Organizer
      第65回日本呼吸器学会・日本結核病学会九州支部秋期講演会
    • Place of Presentation
      熊本(熊本市民会館)
    • Year and Date
      2010-11-12
    • Related Report
      2011 Final Research Report
  • [Presentation] 良きがん化学療法をめざして分子標的薬におけるPK/PD解析2010

    • Author(s)
      濱田哲暢
    • Organizer
      九州山口薬学会ファーマシューティカルケア研修会
    • Place of Presentation
      別府(ビーコンプラザ)
    • Year and Date
      2010-02-13
    • Related Report
      2011 Final Research Report
  • [Presentation] 慢性腎不全モデルラットにおけるイマチニブ体内動態に及ぼす尿毒症物質の影響2010

    • Author(s)
      内田隆
    • Organizer
      日本薬学会九州支部大会
    • Place of Presentation
      長崎大学(長崎)
    • Related Report
      2010 Annual Research Report
  • [Presentation] エルロチニブ体内動態の個体間変動に関与する薬物トランスポータの遺伝多型解析2010

    • Author(s)
      甲斐由貴
    • Organizer
      日本薬学会九州支部大会
    • Place of Presentation
      長崎大学(長崎)
    • Related Report
      2010 Annual Research Report
  • [Presentation] イマチニブ体内動態に及ぼす有機アニオントランスポータOATP1A2およびSLCO1A2 SNPsの影響2010

    • Author(s)
      山川裕司
    • Organizer
      日本臨床薬理学会年会
    • Place of Presentation
      京都国際会館(京都)
    • Related Report
      2010 Annual Research Report
  • [Presentation] Association between intracellular accumulation of imatinib in leukocyte and therapeutic efficacy in patients with chronic myeloid leukemia (CML)2010

    • Author(s)
      南部健
    • Organizer
      日本薬物動態学会
    • Place of Presentation
      大宮ソニックシティ
    • Related Report
      2010 Annual Research Report
  • [Presentation] The role of organic anion-transporting polypeptide (OATP) 1A2 and polymorphisms in imatinib pharmacokinetics2010

    • Author(s)
      山川裕司
    • Organizer
      日本薬物動態学会
    • Place of Presentation
      大宮ソニックシティ
    • Related Report
      2010 Annual Research Report
  • [Presentation] Effect of uremic toxins on the pharmacokinetics of imatinib in renal failure2010

    • Author(s)
      内田隆
    • Organizer
      日本薬物動態学会
    • Place of Presentation
      大宮ソニックシティ
    • Related Report
      2010 Annual Research Report
  • [Presentation] Personalized medicine for non-small cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib2010

    • Author(s)
      Akinobu Hamada
    • Organizer
      American Association for Cancer Research
    • Place of Presentation
      Washington DC, USA
    • Related Report
      2010 Annual Research Report
  • [Presentation] SLCO1B3遺伝子多型に基づいた分子標的薬イマチニブの母集団薬物動態解析2009

    • Author(s)
      山川裕司
    • Organizer
      日本薬学会九州支部大会
    • Place of Presentation
      九州大学(福岡)
    • Year and Date
      2009-12-12
    • Related Report
      2009 Annual Research Report
  • [Presentation] PK/PD解析から見た抗がん剤の効果・副作用分子標的薬の至適投与設計法の開発2009

    • Author(s)
      濱田哲暢
    • Organizer
      医療薬学フォーラム
    • Place of Presentation
      京都国際会館(京都)
    • Year and Date
      2009-12-12
    • Related Report
      2009 Annual Research Report
  • [Presentation] 非小細胞肺癌に対する上皮増殖因子受容体チロシンキナーゼ阻害薬の有害事象と薬物動態との相関解析に基づく個別投与設計の開発2009

    • Author(s)
      濱田哲暢
    • Organizer
      日本臨床薬理学会年会
    • Place of Presentation
      パシフィコ横浜(横浜)
    • Year and Date
      2009-12-05
    • Related Report
      2009 Annual Research Report
  • [Presentation] IMPACT OF SLCO1B3 POLYMORPHISM ON THE POPULATION PHARMACOKINETIC MODEL FOR IMATINIB AT STEADY-S TATE2009

    • Author(s)
      山川裕司
    • Organizer
      日本薬物動態学会年会
    • Place of Presentation
      京都国際会館(京都)
    • Year and Date
      2009-11-27
    • Related Report
      2009 Annual Research Report
  • [Presentation] Pharmacokinetics and Pharmacodynamics, PK/PD of anticancer drugs for personalized medicine2009

    • Author(s)
      Akinobu Hamada
    • Organizer
      International Symposium2009 "New Perspectives in Cancer Research"
    • Place of Presentation
      Ulsan, Korea
    • Year and Date
      2009-11-14
    • Related Report
      2011 Final Research Report
  • [Presentation] Pharmacokinetics and Pharmacodynamics, PK/PD of anticancer drugs for personalized medicine2009

    • Author(s)
      濱田哲暢
    • Organizer
      International Symposium 2009 "New Perspectives in Cancer Rsearch"
    • Place of Presentation
      蔚山大(Ulsan, Korea)
    • Year and Date
      2009-11-14
    • Related Report
      2009 Annual Research Report
  • [Presentation] Association of pharmacokinetics and germ-line mutations in EGFR and ABC transporters with erlotinib toxicity in patients with non-small cell lung cancer (NSCLC)2009

    • Author(s)
      濱田哲暢
    • Organizer
      American Society of Clinical Oncology 2009 Annual Meeting
    • Place of Presentation
      Orange county convention center(Orlando, USA)
    • Year and Date
      2009-05-31
    • Related Report
      2009 Annual Research Report
  • [Presentation] 抗悪性腫瘍薬開発における臨床薬理研究の役割非小細胞肺癌に対する上皮増殖因子受容体チロシンキナーゼ阻害薬の有害事象と薬物動態との相関解析に基づく個別投与設計の開発2009

    • Author(s)
      濱田哲暢
    • Organizer
      第30回日本臨床薬理学会年会
    • Place of Presentation
      横浜(パシフィコ横浜)
    • Related Report
      2011 Final Research Report
  • [Presentation] PK/PD解析から見た抗がん剤の効果・副作用-分子標的薬の至適投与設計法の開発2009

    • Author(s)
      濱田哲暢
    • Organizer
      医療薬学フォーラム2009
    • Place of Presentation
      京都.(京都国際会館)
    • Related Report
      2011 Final Research Report
  • [Presentation] Association of pharmacokinetics and germline mutations in EGFR and ABC transporters with erlotinib toxicity in patients with non-small cell lung cancer(NSCLC)2009

    • Author(s)
      Akinobu Hamada
    • Organizer
      2009Annual meeting American Society of Clinical Oncology
    • Place of Presentation
      Orlando, USA
    • Related Report
      2011 Final Research Report
  • [Patent(Industrial Property Rights)] エルロチニブの副作用又は薬効を判定する方法2009

    • Inventor(s)
      濱田哲暢、佐々木治一郎、齋藤秀之、興梠博次
    • Industrial Property Rights Holder
      国立大学法人熊本大学
    • Industrial Property Number
      2009-116385
    • Filing Date
      2009-05-31
    • Related Report
      2011 Final Research Report
  • [Patent(Industrial Property Rights)] エルロチニブの副作用又は薬効を判定する方法2009

    • Inventor(s)
      濱田哲暢
    • Industrial Property Rights Holder
      熊本大学
    • Industrial Property Number
      2009-116385
    • Filing Date
      2009-05-13
    • Related Report
      2009 Annual Research Report

URL: 

Published: 2009-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi